A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)

Sponsor
Hoffmann-La Roche
Study ID
NCT03399643
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    Atezolizumab is administered via IV 1200 mg every 3 weeks

Study Details

The objective of this study is to investigate the effectiveness of Atezolizumab with a primary focus on the overall survival (OS) rate at 2 years and secondary focuses on quality of life (QoL) and the sequence of treatment in mUC patients. Furthermore, this study aims at collecting data on safety of Atezolizumab and on the reason for cisplatin-ineligibility

Key Dates

First listed
Jan 16, 2018
Start date
Dec 28, 2017
Status verified
Apr 2019
Primary completion
Aug 28, 2018
Completion
Jan 28, 2019

Study Design

Enrollment
22 participants (actual)

Primary Outcome Measure

Overall Survival Rate (OS rate) [ Time Frame: 2 years ]

Find similar trials

Nationwide
Bladder cancer trialsOncology trialsUrology trials

Related Studies